Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Oct;69(10):2865-2866.
doi: 10.4103/ijo.IJO_1477_21.

Central retinal vein occlusion after mRNA SARS-CoV-2 vaccination: A case report

Beatriz Endo  1 , Silvana Bahamon  1 , Dayron F Martínez-Pulgarín  2
Affiliations
Case Reports

Central retinal vein occlusion after mRNA SARS-CoV-2 vaccination: A case report

Beatriz Endo et al. Indian J Ophthalmol. 2021 Oct.

Abstract

A central retinal vein occlusion (CRVO) case in a patient developed with sudden blurred vision in some hemifield areas of his left eye, maintaining 20/20 vision 15-days after the COVID-19 vaccination. Initial retinal findings were venous dilation and tortuosity with dispersing dot hemorrhages. Fluorescein angiography (FA) and optical coherence tomography (OCT) confirmed a non-ischemic CRVO diagnosis, and a complete blood panel was requested with average results. An intravitreal steroid dose was applied. A decrease in best-corrected visual acuity (BCVA) (20/30) with more intraretinal hemorrhages was documented. An intravitreal dose of bevacizumab and oral apixaban were added with a final BCVA of 20/20 with decreased hemorrhages. There is no specific causal relationship between COVID-19 vaccines and CRVO. Without previous risk factors and positive treatment response, this case may correlate the first COVID-19 vaccine dose and the event.

Keywords: COVID-19; CRVO; SARS-Cov2; vaccine.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Admission fluorescein angiography of the left eye showing blocking and hypoperfusion areas in temporal and inferonasal quadrants. Absence of venous filling was evidenced in late phases
Figure 2
Figure 2
Color fundus photography of the left eye showing dot-blot and flame hemorrhages, dilated tortuous veins, and blurred margins in the disc especially in the temporal quadrant
See this image and copyright information in PMC

Comment in

References

    1. Lamb YN. BNT162b2 mRNA COVID-19 vaccine:First approval. Drugs. 2021;81:495–501. - PMC - PubMed
    1. Lahey JM, Tunç M, Kearney J, Modlinski B, Koo H, Johnson RN, et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology. 2002;109:126–31. - PubMed
    1. European Medicines Agency. COVID-19 Vaccine Janssen:EMA finds possible link to very rare cases of unusual blood clots with low blood platelets, 2021. [Last accessed on 2021 Apr 23]. Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-pos... .
    1. Merchant HA. CoViD vaccines and thrombotic events:EMA issued warning to patients and healthcare professionals. J Pharm Policy Pract. 2021;14:32. - PMC - PubMed
    1. Carli G, Nichele I, Ruggeri M, Barra S, Tosetto A. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Intern Emerg Med. 2021;16:803–4. - PMC - PubMed

Publication types